Maricann Group Inc. Signs Definitive Agreement with Lovell Drugs for Medical Cannabis Retail Pharmacy Initiative
Maricann Files Third Quarter Financial Results, Updates Ongoing German License Progress and Distribution Efforts
aricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) "Maricann" or the "Company") is pleased to announce that it has entered into a definitive agreement with Lovell Drugs Limited ("Lovell Drugs"), Ontario's oldest pharmacy chain, to be the exclusive provider of medical cannabis to its pharmacies.
Lovell Drugs will, in partnership with Maricann, implement a medical cannabis education and access program for its pharmacists and allied community physicians that facilitates the counselling and fulfillment of medical cannabis to its patients. Maricann will fulfill prescriptions directly to Lovell Drugs' patients through the existing Access to Cannabis for Medicinal Purposes Regulations. Lovell Drugs has already commenced distribution of Maricann cannabis products to its patients, with the first prescription registered and fulfilled on December 1st, 2017.
Maricann Group, Inc. Adopts a Connected Enterprise Solution from Rockwell Automation to Produce Consistent, High-Yield Crop in Medicinal Cannabis Industry
TORONTO, Ontario, November 30, 2017 —Maricann Group Inc. (CSE:MARI, OTCQB: MRRCF, Frankfurt: 75M “Maricann” or the “Company”) filed its financial statements for the 3 months ending September 30, 2017, with results that were consistent with our expectations. Revenue is expected to increase in the first quarter of 2018 when the Company’s joint pharmacy initiative is expected to launch.
Maricann Group Inc. Receives Encapsulated Cannabis Oil Licence from Health Canada
TORONTO, ON-- November 22, 2017 - Maricann Group Inc. (CSE: MARI) (CSE: MARI.CN) (CNSX: MARI) (OTCQB: MRRCF) (FRANKFURT: 75M) ("Maricann" or the "Company"), a medicinal cannabis company, is working with Rockwell Automation (NYSE: ROK) to develop a connected, scalable plant-wide platform to connect the key functions of Maricann's cultivation facility to produce a consistent, high-yield crop.
Maricann Provides Update on Financing
Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) ("Maricann" or the "Company") through its wholly owned subsidiary, Maricann Inc. has commenced production of encapsulated cannabis oil, following receipt of its production license from Health Canada on November 17, 2017. Maricann expects patients to be able to order oil capsules starting in Q1 2018, subject to Health Canada's issuance of the required license to sell.
TORONTO, Ontario, October 24, 2017 – Maricann Group Inc. (CSE:MARI, OTCQB:MRRCF, FRANKFURT:75M, “Maricann” or the “Company”) announces that it has amended the terms of its previously announced private placement offering (the “Offering”) of convertible debenture units (the “Convertible Debenture Units”) to increase the size of the Offering from up to $20,000,000 aggregate principal amount of Convertible Debenture Units to up to $26,000,000 (or up to $31,000,000, factoring in the full exercise of the Agents’ Option (as defined below)). The amendment will accommodate and include a broader group of investors.